Trial Profile

A Phase III Randomized Controlled Trial to Compare BL-B01D1 With Physician's Choice of Chemotherapy (Last Line) in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Previously Treated With PD-1/PD-L1 Monoclonal Antibody and at Least Two Lines of Chemotherapy (at Least One Line of Platinum-based Chemotherapy)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Izalontamab brengitecan (Primary) ; Capecitabine; Docetaxel; Gemcitabine
Indications Carcinoma; Nasopharyngeal cancer
Focus Registrational; Therapeutic Use
Sponsors Sichuan Baili Pharmaceutical

24 Oct 2025 According to SystImmune media release, results published in The Lancet.
24 Oct 2025 According to SystImmune media release, data presented at the venue of the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin.
24 Oct 2025 Results published in the SystImmune Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com